|
|
| | CID 2745687 Basic information |
| Product Name: | CID 2745687 | | Synonyms: | CID 2745687;Methyl 1-(2,4-Difluoro-phenyl)-5-((4-tert-butyl-thioseMicarbazono)Methyl)-1H-pyrazole-4-carboxylate;methyl 5-[(E)-(tert-butylcarbamothioylhydrazono)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate;1H-Pyrazole-4-carboxylic acid, 1-(2,4-difluorophenyl)-5-[[2-[[(1,1-dimethylethyl)amino]thioxomethyl]hydrazinylidene]methyl]-, methyl ester;GPCR,CID-2745687,CID2745687,G Protein-coupled Receptors,inhibit,Inhibitor,CID 2745687,Arrestin,GPR35 antagonist;methyl 5-({[(tert-butylcarbamothioyl)amino]imino}methyl)-1-(2,4-difluorophenyl)-1H-pyrazole-4-carboxylate;CID 2745687, 10 mM in DMSO;Methyl 5-((2-(tert-butylcarbamothioyl)hydrazono)methyl)-1-(2,4-difluorophenyl)-1H-pyrazole-4-carboxylate | | CAS: | 264233-05-8 | | MF: | C17H19F2N5O2S | | MW: | 395.43 | | EINECS: | | | Product Categories: | Aromatics, Diagnostic and Labeling Agents, Pharmaceuticals, Intermediates & Fine Chemicals | | Mol File: | 264233-05-8.mol |  |
| | CID 2745687 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | crystalline solid | | color | Off-white to light yellow | | InChI | 1S/C17H19F2N5O2S/c1-17(2,3)22-16(27)23-20-9-14-11(15(25)26-4)8-21-24(14)13-6-5-10(18)7-12(13)19/h5-9H,1-4H3,(H2,22,23,27)/b20-9+ | | InChIKey | CYNLZIBKERMMOA-AWQFTUOYSA-N | | SMILES | COC(=O)c1cnn(-c2ccc(F)cc2F)c1\C=N\NC(=S)NC(C)(C)C |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | CID 2745687 Usage And Synthesis |
| Description | GPR35 is a G protein-coupled receptor that is activated by kynurenic acid and 2-acyl lysophosphatidic acids (e.g., 2-oleoyl lysophosphatidic acid). It is expressed predominantly on immune cells, the brain, and in the gastrointestinal tract. GPR35 is overexpressed in gastric cancer cells. CID-2745687 is a reversible, competitive antagonist of GPR35, blocking activation by the synthetic agonist pamoic acid with a Ki value of 12.8 nM. It less potently blocks activation of GPR35 by zaprinast (IC50 = 160 nM). It shows ~57-fold selectivity for GPR35 over the related receptor GPR55 (IC50 = 9.08 μM). | | Uses | CID 2745687 is used as a GPR35 antagonist, with potential application towards immune or gastrointestinal system regulation. | | Definition | ChEBI: 5-[[[(tert-butylamino)-sulfanylidenemethyl]hydrazinylidene]methyl]-1-(2,4-difluorophenyl)-4-pyrazolecarboxylic acid methyl ester is a ring assembly and a member of pyrazoles. | | in vitro | previous study indicated that both cid-2745687 and ml-145 could competitively inhibit the effects of cromolyn disodium and zaprinast (two agonists sharing an overlapping binding site) on human gpr35. in contrast, though ml-145 antagonized the effects of pamoate competitively, cid-2745687 showed a noncompetitive fashion. additionally, neither ml-145 nor cid-2745687 was able to antagonize the agonist effects at rodent ortholog of gpr35 [1]. | | in vivo | to test whether gpr35 contributes to the metabolic effect of zaprinast, the retina from cngb1/ mice was preincubated with a gpr35 antagonist, cid-2745687, followed by an additional zaprinast treatment. results showed that cid-2745687 did not block the effect of zaprinast on glutamate and aspartate. moreover, pamoic acid, the gpr35 agonist, did not change aspartate or glutamate levels [1]. | | storage | Store at -20°C | | references | [1] jenkins l,harries n,lappin je,mackenzie ae,neetoo-isseljee z,southern c,mciver eg,nicklin sa,taylor dl,milligan g. antagonists of gpr35 display high species ortholog selectivity and varying modes of action. j pharmacol exp ther.2012 dec;343(3):683-95.
[2] du j,cleghorn wm,contreras l,lindsay k,rountree am,chertov ao,turner sj,sahaboglu a,linton j,sadilek m,satrústegui j,sweet ir,paquet-durand f,hurley jb. inhibition of mitochondrial pyruvate transport by zaprinast causes massive accumulation of aspartate at the expense of glutamate in the retina. j biol chem.2013 dec 13;288(50):36129-40. |
| | CID 2745687 Preparation Products And Raw materials |
|